SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as investors react to the company's recent breakout above key resistance levels and institutional buying, fueled by anticipation of upcoming clinical data. The community is actively debating the company's massive addressable market in lung cancer and the potential for a short squeeze, while highlighting the company's strong institutional ownership and long-term potential as a standalone oncology leader or acquisition target.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is facing intense market volatility as it slips below the key psychological threshold of one dollar, fueling heated debate among investors regarding its long-term viability and the impact of potential token dilution. While some community members view the price dip as an accumulation opportunity and remain bullish on future regulatory clarity, others are increasingly vocal about their frustration and skepticism toward the project's leadership.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending as investors monitor its critical role as infrastructure for real-world asset tokenization and institutional adoption, alongside active community debate regarding its price action relative to Bitcoin. The conversation is heavily driven by hopes for the Clarity Act's passage and excitement surrounding high-profile partnerships, though retail sentiment remains mixed between long-term conviction and frustration over recent stagnant performance.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is experiencing significant momentum driven by strong institutional interest, upward guidance revisions, and a favorable supply-demand outlook for lithium. The community is actively debating the stock's long-term potential as a cornerstone of energy infrastructure, while technical traders monitor critical support levels following recent volatility.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

Investors are closely monitoring New Era Energy & Digital as construction permits for the Texas Critical Data Center project were confirmed, acting as a major de-risking milestone that fuels bullish sentiment. While the stock experiences volatility following earnings results, the community is actively debating the company's transition into AI infrastructure and potential power purchase agreements, with many focusing on the strategic value of its behind-the-meter energy assets.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines is trending due to the announcement of a massive defense spending bill and anticipation of government contracts, with the community actively discussing institutional backing and potential domestic drone manufacturing mandates. Investors are closely tracking a new performance-based compensation plan for the CEO that ties major stock targets to future growth, fueling speculation about the company's long-term potential in the defense supply chain.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is trending as retail traders debate whether the current price represents an extreme buying opportunity or a structural risk due to the nature of leveraged ETFs. Community sentiment is deeply divided, with many actively averaging down or holding massive positions while others warn of volatility decay and the potential for a reverse stock split.

BitGo Holdings, Inc. operates as a digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. It focuses on accelerating the transition of the financial system to a digital asset economy. The company was founded by Michael Belshe and Ben Davenport in 2013 and is headquartered in Sioux Falls, SD.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo Holdings is facing heavy retail skepticism and extreme volatility following a rocky IPO, with the community actively debating whether the stock is a long-term infrastructure play or a manipulated asset. While some investors point to a recent share buyback program and institutional partnerships as catalysts for a potential short squeeze or recovery, others remain wary of poor earnings reports and downward price trends.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing extreme volatility as investors digest a mixed quarterly report that featured record backlog growth alongside an earnings miss and mission delays. The community remains deeply polarized, with some bulls emphasizing the company's strong long-term backlog as a buying opportunity, while others express significant concern over cash burn, dilution risks, and immediate downward pressure on the stock.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is trending as the community closely monitors its expanding renal pipeline following the FDA's decision to grant a rolling review for povetacicept in IgA nephropathy. Investors are expressing optimism regarding the company's long-term growth prospects while debating current commercial execution and pricing strategies for its newer product launches.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2026, and provided a business update. We continue to execute against our strategy of building a...

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation Committee of the Companys Board of Directors (the Compensation Committee) granted...

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being...

What This Immunome Sale Means a Day Before a Big FDA Milestone

Key PointsAn Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026...

Immunome Stock Up 32% in a Month: Here's What You Should Know

IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.

Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review

FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date backed by positive Phase 3 data.read more...

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational...

Immunome, Inc. (the Company) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Companys Board of Directors (the Compensation Committee) granted inducement...

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed...

4 Biotech Stocks Investors Should Watch in 2026

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector. 

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

Why Is IMNM Stock Rising Today?

Equity

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.60	--	--	N/A
Q2 '26	-$0.51	-$0.65	-26.50%	MISSED
Q1 '26	-$0.56	-$0.48	13.69%	BEAT
Q4 '25	-$0.59	-$0.76	-28.78%	MISSED
Q3 '25	-$0.57	-$0.65	-14.93%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings